The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I
as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17β-hydroxy steroid dehydrogenase type 1.
本发明涉及新的2-取代的Estra-1,3,5(10)-
三烯-17-酮化合物I及其药学上可接受的盐,其制备方法以及作为药物用于预防和/或治疗可以通过抑制17β-羟基类
固醇脱氢酶1型而受到影响的
雌激素依赖性疾病。